Breast Cancer

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Those who took olanzapine reported higher levels of satisfaction than patients on placebo.

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Because oncology nurses are at the forefront of patient care, they are uniquely positioned to facilitate cancer survivorship and lymphedema prevention.

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.

Oncology nurses can help advocate for AI-assisted diagnostic improvements.

Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.

Assessment of psychological needs and offering tailored interventions immediately after BCS helps patients with breast cancer in the outpatient setting.

Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP, discusses the role of oncology nurses in genomic testing.